| Market Cap | 181.09M | P/E | - | EPS this Y | -8.00% | Ern Qtrly Grth | - |
| Income | -99.22M | Forward P/E | -10.65 | EPS next Y | 40.90% | 50D Avg Chg | 23.00% |
| Sales | 501.06M | PEG | - | EPS past 5Y | 14.28% | 200D Avg Chg | -5.00% |
| Dividend | N/A | Price/Book | 0.66 | EPS next 5Y | - | 52W High Chg | -74.00% |
| Recommedations | 2.30 | Quick Ratio | 0.17 | Shares Outstanding | 26M | 52W Low Chg | 93.00% |
| Insider Own | 13.48% | ROA | -2.92% | Shares Float | 23.22M | Beta | 3.39 |
| Inst Own | 17.26% | ROE | -43.15% | Shares Shorted/Prior | 1.30M/1.61M | Price | 7.03 |
| Gross Margin | 22.56% | Profit Margin | -19.80% | Avg. Volume | 496,050 | Target Price | 5.33 |
| Oper. Margin | -17.29% | Earnings Date | Dec 9 | Volume | 179,131 | Change | -0.85% |
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company offers research and discovery services, including computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services, as well as model and research services. The company operates in the United States, the Netherlands, and internationally. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.
| Lake Street | Buy | Sep 30, 24 |
| Lake Street | Hold | May 16, 24 |
| Craig-Hallum | Buy | May 16, 24 |
| Jefferies | Hold | May 14, 24 |
| Jefferies | Buy | Feb 9, 24 |
| Craig-Hallum | Buy | Dec 12, 23 |
| Wells Fargo | Overweight | Jul 20, 23 |
| Jefferies | Hold | Jan 19, 23 |
| Lake Street | Buy | Jan 11, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Garrett Michael | Chief Commercial Off.. Chief Commercial Officer | Dec 14 | Buy | 2.829 | 5,000 | 14,145 | 16,467 | 12/15/23 |
| Beattie John Gregory | Chief Operating Offi.. Chief Operating Officer | Dec 14 | Buy | 3.1238 | 47,966 | 149,836 | 111,761 | 12/15/23 |
| Pitchford William D | Chief Human Resource.. Chief Human Resources Officer | Dec 09 | Sell | 5.8246 | 2,123 | 12,366 | 74,051 | 12/29/22 |
| Neff R Matthew | Director Director | Dec 01 | Sell | 6.12 | 1,000 | 6,120 | 62,388 | 12/02/22 |
| Harkness James | Chief Operating Offi.. Chief Operating Officer, RMS | Mar 15 | Buy | 19.29 | 38,968 | 751,693 | 38,968 | 03/16/22 |
| Downing Philip A | Sr. VP, Preclinical.. Sr. VP, Preclinical Srvcs. | Feb 22 | Buy | 23.9728 | 2,000 | 47,946 | 42,195 | 02/23/22 |
| Taylor Beth | VP- Finance & CFO VP- Finance & CFO | Feb 18 | Buy | 23.0715 | 5,000 | 115,358 | 83,875 | 02/22/22 |
| Davis Gregory Cole | Director Director | Feb 17 | Buy | 21.87 | 5,000 | 109,350 | 37,683 | 02/22/22 |
| Garrett Michael | Chief Commercial Off.. Chief Commercial Officer | Feb 18 | Buy | 23.5 | 1,000 | 23,500 | 1,000 | 02/22/22 |
| Pitchford William D | Chief HR Officer Chief HR Officer | Feb 18 | Buy | 21.12 | 3,500 | 73,920 | 76,174 | 02/18/22 |
| Beattie John Gregory | Chief Operating Offi.. Chief Operating Officer | Feb 16 | Buy | 22.93 | 11,400 | 261,402 | 42,794 | 02/18/22 |
| Leasure Robert Jr. | President and CEO President and CEO | Feb 17 | Buy | 23.0262 | 5,000 | 115,131 | 285,216 | 02/17/22 |
| Sagartz John E | Chief Strategy Offic.. Chief Strategy Officer | Feb 15 | Buy | 19.95 | 2,506 | 49,995 | 681,030 | 02/17/22 |
| Johnson Richard Allen | Director Director | Aug 02 | Option | 1.4 | 25,000 | 35,000 | 67,683 | 02/07/22 |
| Downing Philip A | Sr. VP, Preclinical.. Sr. VP, Preclinical Srvcs. | Dec 22 | Sell | 43.0412 | 3,057 | 131,577 | 40,195 | 01/12/22 |